PMID- 33002548
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20221207
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 170
DP  - 2020 Dec
TI  - Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A 
      simplified approach to glycemic control in type 2 diabetes mellitus.
PG  - 108478
LID - S0168-8227(20)30731-2 [pii]
LID - 10.1016/j.diabres.2020.108478 [doi]
AB  - Approximately 50% of patients with type 2 diabetes mellitus (T2DM) do not achieve 
      glycemic targets and require treatment intensification. A fixed-ratio combination 
      of a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with basal insulin, such 
      as lixisenatide with insulin glargine (iGlarLixi), exploits the complementary 
      mechanisms of action of each component to address hyperglycemia while mitigating 
      potential adverse events (AEs). The iGlarLixi dose is titrated considering the 
      effect of basal insulin on fasting plasma glucose, and the fixed-ratio 
      combination ensures that the lixisenatide dose never exceeds 20 mug/day. We 
      describe the characteristics of iGlarLixi therapy, based on the LixiLan clinical 
      program, and provide guidance on the characteristics of patients likely to 
      benefit from such treatment in routine clinical practice. In the phase III 
      LixiLan trials, iGlarLixi resulted in significantly greater reductions in 
      glycated hemoglobin (HbA1c), better achievement of HbA1c targets, less glycemic 
      variability versus insulin glargine, lixisenatide or GLP-1 RA alone, and was 
      associated with weight control, less hypoglycemia versus insulin glargine, and 
      fewer GI AEs versus lixisenatide. Findings were consistent regardless of age, 
      diabetes duration, and baseline HbA1c. The efficacy, safety, and convenient 
      once-daily administration schedule of iGlarLixi make it a valuable treatment 
      option for patients with T2DM requiring treatment intensification.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Giorgino, Francesco
AU  - Giorgino F
AD  - Department of Emergency and Organ Transplantation, Section of Internal Medicine, 
      Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, 
      Piazza Umberto I, 1, 70121 Bari BA, Italy. Electronic address: 
      francesco.giorgino@uniba.it.
FAU - Caruso, Irene
AU  - Caruso I
AD  - Department of Emergency and Organ Transplantation, Section of Internal Medicine, 
      Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, 
      Piazza Umberto I, 1, 70121 Bari BA, Italy.
FAU - Napoli, Raffaele
AU  - Napoli R
AD  - Department of Translational Medical Sciences, Federico II University School of 
      Medicine, Via Sergio Pansini, 5, 80131 Napoli NA, Italy. Electronic address: 
      Raffaele.napoli@unina.it.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200928
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Blood Glucose)
RN  - 0 (Drug Combinations)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Peptides)
RN  - 2ZM8CX04RZ (Insulin Glargine)
RN  - 74O62BB01U (lixisenatide)
SB  - IM
MH  - Blood Glucose/analysis/drug effects
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Drug Combinations
MH  - Female
MH  - Glucagon-Like Peptide-1 Receptor/agonists/metabolism
MH  - Glycated Hemoglobin/analysis
MH  - Glycemic Control/methods
MH  - Humans
MH  - Hyperglycemia/drug therapy
MH  - Hypoglycemia/chemically induced/epidemiology
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Insulin Glargine/*administration & dosage
MH  - Male
MH  - Peptides/*administration & dosage
OTO - NOTNLM
OT  - Bodyweight
OT  - Fixed-ratio combination
OT  - Hypoglycemia
OT  - Insulin glargine
OT  - Lixisenatide
OT  - Type 2 diabetes
COIS- Declaration of Competing Interest The authors declare the following financial 
      interests/personal relationships which may be considered as potential competing 
      interests: FG has received consulting fees from AstraZeneca, Boehringer 
      Ingelheim, Eli Lilly, Novo Nordisk, Roche Diabetes Care, and Sanofi; and has 
      received research support from Eli Lilly, Lifescan and Takeda. IC and RN have no 
      conflicts of interest to disclose in relation to the content of the current 
      manuscript.
EDAT- 2020/10/02 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/10/01 20:11
PHST- 2020/07/03 00:00 [received]
PHST- 2020/09/11 00:00 [revised]
PHST- 2020/09/20 00:00 [accepted]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
PHST- 2020/10/01 20:11 [entrez]
AID - S0168-8227(20)30731-2 [pii]
AID - 10.1016/j.diabres.2020.108478 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2020 Dec;170:108478. doi: 10.1016/j.diabres.2020.108478. 
      Epub 2020 Sep 28.